News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
4D Molecular Therapeutics (4DMT) Acquires Rights to Penn Medicine Invented Technology from Aevitas Therapeutics
Penn spinout Aevitas Therapeutics recently executed an asset purchase agreement with California-based biotechnology company 4D Molecular Therapeutics (4DMT).
Adult Schizophrenia Drug Wins FDA Approval
Teva Pharmaceuticals and MedinCell recently received approval from the U.S. Food and Drug Administration (FDA) for UZEDY™ (risperidone).
Cabaletta Bio Receives FDA Fast Track Designation for CABA-201 Drug to Target Autoimmune Diseases
Cabaletta Bio received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for its drug CABA-201.
Verismo Therapeutics Activates its STAR-101 Clinical Trial to Evaluate Investigational Drug SynKIR-110
Penn spinout Verismo Therapeutics, which focuses on CAR T-cell therapy for solid tumors, has activated its STAR-101 Phase 1 clinical trial at Penn.
PCI’s Carter Caldwell Is Interviewed on Launching a Startup
PCI’s Carter Caldwell, program director for the Penn Medicine Co-Investment Program, discussed his entrepreneurial career and shared advice for others looking to start businesses.
Penn Today Highlights How Penn Research Powers Numerous FDA-approved Treatments
From CAR-T therapy to the mRNA covid-19 vaccine, the list of Penn-linked FDA approvals has been growing with each passing year.
PCI features the Future of Wearable Technology during Philly Tech Week
On May 9th, PCI and the Philadelphia Alliance for Capital and Technologies (PACT) co-hosted the event "The Future of Wearable Technology" at the Pennovation Center as part of Philly Tech Week 2023
SAFELab takes space at Pennovation Center
SAFELab is a research initiative focused on examining the ways in which youth of color navigate violence on and offline.
Meet the 2023/2024 PCI Fellows Cohort
Eleven fellows were admitted to the 2023/2024 cohort out of a large application pool.
Penn Medicine Magazine Showcases Penn’s Drug Research and Development and Commercial Partnerships
The Spring 2023 issue of Penn Medicine Magazine describes how Penn has become a hub for drug research and development and created the infrastructure in both supporting clinical research and forging co